Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally.
Halozyme Therapeutics stock last closed at $33.20, up 0.18% from the previous day, and has decreased 28.76% in one year. It has underperformed other stocks in the Biotechnology industry by 0.3 percentage points. Halozyme Therapeutics stock is currently +11.22% from its 52-week low of $29.85, and -44.16% from its 52-week high of $59.46.
There are currently 131.68M HALO shares outstanding. The market cap of HALO is $4.37B. In the last 24 hours, 671,780 HALO shares were traded.
How to Buy Halozyme Therapeutics Stock
Not sure how to invest in Halozyme Therapeutics stock? Here's how.
Choose where to buy Halozyme Therapeutics stock: You need to pick a stock brokerage, but don't worry - we've sifted through dozens of online stock brokerages and apps to help you choose where to buy Halozyme Therapeutics stock.
Sign up for your brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've found.
Put funds into your investment account: Pick your method of payment and add your information.
Analyze Halozyme Therapeutics stock: The Halozyme Therapeutics ticker symbol is HALO. Is Halozyme Therapeutics stock a good investment? Should you buy shares of HALO? How do HALO's underlying business fundamentals look? Do top analysts think Halozyme Therapeutics is a good buy? Why has HALO's stock price moved recently? (Hint: Our stock research website can help you understand if HALO is a good stock to buy).
Place your HALO buy order: Decide if you will purchase HALO shares at the current market price or use a limit order to purchase HALO stock at a particular price.
Get the latest news on your investment in HALO: Create a watchlist to monitor your investment in Halozyme Therapeutics shares.
Step 1: Choose where to buy Halozyme Therapeutics stock
You need a brokerage account to access the NASDAQ market and buy HALO stock.
A brokerage account enables you to buy and sell a number of financial instruments, such as stocks, bonds, mutual funds, and ETFs.
Our recommended brokerage: eToro
Based on our analysis, eToro is the best place to buy stocks. Here's why:
You can invest in stocks with zero commissions: Invest without commissions.
Buy fractional shares: Even if you don't have the money to buy a full share, you can still buy the stock.
Access to world financial markets: From Tech to Utilities, New York to London — you can fill your portfolio with stocks from the world's leading stock exchanges.
Social investing: eToro boasts a community with more than 20 million users around the world. Talk to, learn from, and copy the unique crypto portfolios of other investors.
Security: eToro is a regulated and licensed brokerage platform.
Buy other financial assets: Such as ETFs and cryptocurrencies.
Get $10 towards your stock purchase by signing up for an account with eToro now.
eToro securities trading is offered by eToro USA Securities, Inc. (“the BD”), member of FINRA and SIPC. Cryptocurrency is offered by eToro USA LLC (“the MSB”) (NMLS: 1769299) and is not FDIC or SIPC insured. Investing involves risk, and content is provided for educational purposes only, does not imply a recommendation, and is not a guarantee of future performance. https://www.wallstreetzen.com is not an affiliate and may be compensated if you access certain products or services offered by the MSB and/or the BD.
Step 2: Sign up for your brokerage account
Now that you've picked the best brokerage, the next step is to fill out some personal information so you are able to buy HALO today.
After you have chosen the best place to buy Halozyme Therapeutics stock, it's crucial to evaluate their stock before you buy, so you actually comprehend the risk and opportunity.
Halozyme Therapeutics Metrics
HALO Price
$33.20
1w %
-1.98%
1y %
-28.76%
5y %
83.12%
P/E
24.96x
P/B
66.39x
P/S
6.36x
PEG
0.42x
Revenue
$704.98M
Earnings
$181.64M
Fore. Rev. Growth
19.66%
Fore. Earn. Growth
60.05%
Market Cap
$4.37B
Next Earnings
N/A
Next Dividend
N/A
HALO Zen Score
WallStreetZen was created to help part-time investors perform more in-depth fundamental analysis quickly.
There are more short-term assets than short-term liabilities on the HALO balance sheet.
HALO earnings of $246.48M is not sufficient to cover its interest payments.
Signs that HALO is not financially healthy:
There are more long-term liabilities than short-term assets on the HALO balance sheet.
HALO profit margin has gone down from 92.2% to 25.8% in the past year.
HALO has a relatively high debt to equity ratio of 24.81.
HALO's operating cash flow of $279.28M allows it to safely service it's debt of $1.49B.
Total HALO debt is higher than 5 years ago, relative to shareholder equity.
Do Wall Street analysts think it's a good time to buy Halozyme Therapeutics stock
Out of 8 Equities analysts who monitor HALO, the consensus analyst rating on Halozyme Therapeutics is a Strong Buy
It's important to note that analyst forecasts are not stock recommendations, nor are they investment advice.
Latest HALO Analyst Recommendations
Jason Butler, a bottom 17% analyst from JMP Securities reiterates HALO with a buy rating and maintains their HALO price target from $66.00 to $66.00, on May 10, 2023.
Vikram Purohit, a bottom 12% analyst from Morgan Stanley maintains HALO with a strong buy rating and lowers their HALO price target from $64.00 to $60.00, on May 10, 2023.
Joseph Catanzaro, a bottom 9% analyst from Piper Sandler upgrades HALO to a strong buy rating and announces their HALO price target of $46.00, on May 10, 2023.
Caroline Palomeque, a top 31% analyst from Berenberg reinstates HALO with a strong buy rating and announces their HALO price target of $58.00, on Mar 27, 2023.
Mohit Bansal, a top 13% analyst from Wells Fargo maintains HALO with a strong buy rating and lowers their HALO price target from $55.00 to $48.00, on Mar 17, 2023.
Last year, HALO earnings were $181.64M. Over the past 5 year, HALO's earnings have grown by 21.13% per year. This was faster than the Biotechnology industry average of 18.73%.
Last year, HALO revenue was $704.98M. Over the past 5 year, HALO's revenue has increased by 17.27% per year. This was slower than the Biotechnology industry average of 89.01%.
In the past year, insiders at HALO have sold more shares than they have bought.
Michael J. Labarre, SVP CHIEF TECHNICAL OFFICER of HALO, was the latest HALO insider to sell. They sold $360,000.00 worth of HALO shares on Apr 18, 2023.
No, Halozyme Therapeutics doesn't provide an income stream by paying out dividends.
What others are saying about HALO
One of the major reasons eToro is our favorite brokerage is because of its social trading community.
Click below to find out what other investors have to say.
Step 5: Place your HALO buy order
There are two primary types of orders:
Market order: A market order is an order to buy or sell a stock at the best price on the market. Market orders are usually sufficient.
Limit order: A limit order is an order to buy or sell a security at a specific price (or better). If you want to make sure you're buying or selling at a particular price, use a limit order.
Hit the Open button and eToro will place the order.
If you want additional help with buying stocks on eToro, watch the helpful video below:
How much does it cost to buy one Halozyme Therapeutics share?
As of May 26, 2023, it costs $33.20 to buy one share of Halozyme Therapeutics stock.
Remember, eToro's fractional share buying allows you to buy partial shares of stocks and ETFs. Even if you only have $10, you can buy 0.301 shares of HALO.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.